|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心

研究人員開發了一種高特異性的CDC7抑製劑TAK-931作為臨床腫瘤治療劑，抗腫瘤藥效研究通過hjc黄金城進行

2023-07-05
|
訪問量：

44.png

Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. 

Medicilon has established a complete evaluation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.

Reference:

Kenichi Iwai, A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197. 


相關新聞